GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
GUIDED THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.16−0.03 (-15.79%)
Close on Oct 19, 2026
- Market cap
- $15.45M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0701 (−30.47%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
GUIDED THERAPEUTICS INC grew revenue 450.8% to $650.00K over the twelve months to Jun 30, 2026. Free cash flow was -$1.07M.
Revenue
$650.00K
+450.8% vs. a year earlier
Operating income
-$1.98M
TTM Q2 2026
Free cash flow
-$1.07M
FY2025
EPS, diluted
-$0.04
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $15.45M
- P/E ratio
- –
- Price to sales
- 23.76
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.93%
Fundamentals
- Revenue
- $650.00K
- Net income
- -$3.07M
- EPS, diluted
- -$0.04
- Free cash flow
- -$1.07M
- Book value per share
- -$0.06
- Diluted shares
- 97M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$650.00K+450.8% YoY
Gross profit
$493.00K+540.3% YoY
Operating income
-$1.98M
Net income
-$3.07M
EPS, diluted
-$0.04
Free cash flow
–
Reported periodTrailing twelve months